

Printed as of 12/5/2025

Disclosures

Personal Commercial (9)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|-----------------------------|------------------------------|--------------------------|-------------------------------------|
| Self | | | |
| Alnylam Inc | Research/Research Grants | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| AstraZeneca Pharmaceuticals | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Attralus | Research/Research Grants | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Bridge Bio | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Eidos, Inc | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Intellia | Data Safety Monitoring Board | Significant (>= \$5,000) | Invasive CV Angio and Interventions |
| Ionis | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Novo Nordisk Inc. | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Pfizer | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (5)

| Trial Name | Trial Sponsor | Trial Funding Source |
|------------------|---------------|----------------------|
| DepletTTR | Alexion | |
| Helios-B | Alnylam | |
| REVEAL | Attralus | |
| Magnitude | Intellia | |
| CardioTTransform | Ionis | |

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 7/22/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 7/22/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 7/22/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 7/22/2025

ACC and **Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.